--- the subscriber area has no ads and those above are not selected or endorsed by this site ---


Akoustis 1Q23 results and more -3

09:06 14-Nov-22


The Akoustis conference call has just concluded.  Management forecasts 55-70% growth this quarter, which handily exceeds estimates by over $2.4M.  The jump is due to a demand rebound following supply chain issues.  Also, as I expected with the last quarterly report, management says CBRS demand is ramping, possibly as soon as this quarter, along European and Asian infrastructure.  Design underway on a 10GHz filter for DARPA is also technologically impressive as well.  Akoustis also echoes MACom's comments about chip stimulus, saying that it will probably take a quarter for decisions to be made, and another quarter for funds to be disbursed.

AKTS is down a little over a percent in the pre-market and looks set to trade around $3.50.  I continue to think that next year is when the company really starts to show improved results.  It's possible the stock price will continue to anticipate that, but I remain wary of year end tax loss harvesting.

On 11/14/22 07:45, Esekla wrote:
Akoustis has published results for its fiscal first quarter:
  • a loss of 8 cents per share misses by 8 cents
  • from $5.6M of revenue, which is in line
Management continues to point out the opportunity presented by the CHIPS act, saying it could take production from the current 500M units per year into the billions.  I note that the share count expanded by 10% for the quarter.  AKTS hasn't traded meaningfully so far.  The conference call is a 8am and I will write more if appropriate.

In the meantime, I will also document that Fenics GO from BGC Partners was named OTC Trading Platform of the Year.